Share
University of Pennsylvania senior Patrick Beyrer and 2020 graduate Brook Jiang have been selected as 2021 Yenching Scholars, with full funding to pursue an interdisciplinary master’s degree in China studies at the Yenching Academy of Peking University, in Beijing.
Beyrer and Jiang are among the 117 scholars chosen from 37 countries to enroll in the one-year program in September. Six scholars affiliated with Penn have been chosen since the program’s inception in 2015.
Beyrer, from Rockville Centre, New York, is pursuing a combined bachelor’s and master’s degree in East Asian languages and civilizations with a concentration in Chinese and a minor in science, technology, and society in the School of Arts & Sciences. At Penn, he has been involved in radiology research at the Perlman School of Medicine and was the vice president of mentorship for Penn Transfer Student Organization.
Two Yenching Scholars for Penn
upenn.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from upenn.edu Daily Mail and Mail on Sunday newspapers.
Simphotek, Inc Announces NIH Grant for Development of an In Situ System for Treatment of Mesothelioma
einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.
by
As the news of four vaccine candidates claiming high efficacy levels in field trials cheered up the pandemic-struck globe, India, with more than 9 million confirmed Covid-19 cases, and a battered economy, is getting ready to vaccinate a population of more than a billion people, that too, twice. And that too, quite rapidly, for that is believed to be the sure-shot way to arrest the pandemic spread.
No doubt, India, as the world’s leading vaccine manufacturer, is in a better position vis-à-vis many other developing countries for accessing vaccines. Serum Institute of India alone is planning to produce a billion doses of Novavax vaccine by 2021 and Bharat Biotech Ltd is getting ready to produce its own vaccine soon, but challenges galore in the path: distribution logistics, supply of the right vaccine with a proven efficacy level with no accompanying side-effects and cost of the vaccine.